{"hands_on_practices": [{"introduction": "Timely diagnosis of Human Immunodeficiency Virus (HIV) infection is critical, and identifying the acute phase presents a unique challenge due to the \"window period\" before antibodies are detectable. This exercise simulates a classic diagnostic scenario where modern testing algorithms are essential for early detection. By working through this case [@problem_id:4848448], you will practice interpreting a discordant pattern of results—a reactive initial screen with a negative antibody follow-up—to correctly identify acute HIV infection, a crucial skill for initiating early therapy and preventing transmission.", "problem": "A $27$-year-old man presents with fever, malaise, myalgias, and a diffuse maculopapular rash $13$ days after a single episode of condomless receptive anal intercourse with a new partner. He has no prior Human Immunodeficiency Virus (HIV) testing on record. On examination, he is febrile at $38.5^{\\circ}\\mathrm{C}$, with nonexudative pharyngitis and tender posterior cervical lymphadenopathy. Laboratory evaluation includes a United States Centers for Disease Control and Prevention (CDC)-recommended HIV testing algorithm: an initial $4^{\\text{th}}$-generation Human Immunodeficiency Virus type $1$ and type $2$ (HIV-$1$/HIV-$2$) antigen/antibody combination immunoassay is reactive; the supplemental HIV-$1$/HIV-$2$ antibody differentiation immunoassay is negative for both HIV-$1$ and HIV-$2$ antibodies; a Human Immunodeficiency Virus type $1$ (HIV-$1$) Ribonucleic Acid (RNA) Nucleic Acid Test (NAT) is positive at $2.1 \\times 10^{5}$ copies per milliliter. Hepatitis C virus antibody and rapid plasma reagin are nonreactive. \n\nUsing only fundamental immunologic and virologic principles and well-tested clinical facts as your starting point—namely, that nucleic acid amplification detects viral genomes directly, that antigen detection precedes antibody formation during primary infection, and that seroconversion requires time for clonal expansion and affinity maturation—determine the single best interpretation of this discordant testing pattern and the most appropriate immediate clinical action. Which option is most correct?\n\nA. The reactive screening immunoassay is a false positive due to cross-reactive antibodies; the negative differentiation immunoassay rules out HIV, so defer therapy and repeat all tests in $6$ months.\n\nB. Chronic Human Immunodeficiency Virus type $2$ (HIV-$2$) infection explains the discordance; initiate HIV-$2$-directed antiretroviral therapy (ART) and disregard the HIV-$1$ RNA NAT as nonspecific.\n\nC. Acute Human Immunodeficiency Virus type $1$ (HIV-$1$) infection is present; diagnose acute HIV-$1$, initiate antiretroviral therapy (ART) immediately, provide transmission counseling, and repeat serologic testing in $1$ to $2$ weeks to document seroconversion.\n\nD. The discordance indicates an indeterminate result without sufficient evidence for HIV; await antibody confirmation before any antiretroviral therapy (ART) or counseling.\n\nE. A transient viremia from a non-HIV viral illness caused the positive NAT; provide supportive care only and avoid labeling the patient with HIV until antibodies appear.", "solution": "### Step 1: Extract Givens\n-   **Patient Profile**: A $27$-year-old man.\n-   **Clinical Presentation**: Fever, malaise, myalgias, diffuse maculopapular rash.\n-   **History**: Symptoms began $13$ days after a single episode of condomless receptive anal intercourse with a new partner. No prior Human Immunodeficiency Virus (HIV) testing.\n-   **Physical Examination**: Febrile at $38.5^{\\circ}\\mathrm{C}$, nonexudative pharyngitis, tender posterior cervical lymphadenopathy.\n-   **Laboratory Data (CDC-recommended HIV testing algorithm)**:\n    1.  Initial test: $4^{\\text{th}}$-generation Human Immunodeficiency Virus type $1$ and type $2$ (HIV-$1$/HIV-$2$) antigen/antibody combination immunoassay is reactive.\n    2.  Supplemental test: HIV-$1$/HIV-$2$ antibody differentiation immunoassay is negative for both HIV-$1$ and HIV-$2$ antibodies.\n    3.  Tie-breaker test: Human Immunodeficiency Virus type $1$ (HIV-$1$) Ribonucleic Acid (RNA) Nucleic Acid Test (NAT) is positive at $2.1 \\times 10^{5}$ copies per milliliter.\n-   **Other Laboratory Data**: Hepatitis C virus antibody and rapid plasma reagin are nonreactive.\n-   **Guiding Principles**:\n    1.  Nucleic acid amplification detects viral genomes directly.\n    2.  Antigen detection precedes antibody formation during primary infection.\n    3.  Seroconversion requires time for clonal expansion and affinity maturation.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is evaluated for validity.\n\n1.  **Scientific or Factual Soundness**: The problem is scientifically and factually sound. The clinical presentation (fever, rash, pharyngitis, lymphadenopathy) and timing ($13$ days post-exposure) are classic for an acute retroviral syndrome. The described laboratory testing sequence (initial $4^{\\text{th}}$-gen immunoassay, followed by antibody differentiation, and then a NAT) is the standard algorithm recommended by the United States Centers for Disease Control and Prevention (CDC) for HIV diagnosis. The specific pattern of results (reactive Ag/Ab immunoassay, negative Ab differentiation, positive NAT) is the hallmark of acute HIV-$1$ infection. The viral load of $2.1 \\times 10^{5}$ copies/mL is a realistic and typical finding in this stage. The provided guiding principles are correct tenets of virology and immunology.\n2.  **Well-Posed**: The problem is well-posed. It provides a complete set of clinically and temporally consistent data and asks for the single best interpretation and corresponding clinical action. A unique and correct answer can be derived from the information using established diagnostic principles.\n3.  **Objective**: The problem is expressed in objective, precise, and standard clinical terminology. There are no subjective or opinion-based claims.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. It is a well-constructed clinical vignette that accurately reflects a real-world diagnostic challenge. A definitive solution can be derived from the provided data and principles.\n\n### Derivation of the Correct Interpretation and Clinical Action\n\nThe provided information must be analyzed sequentially, in accordance with the principles of virology and the standard diagnostic algorithm.\n\n1.  **Clinical Context**: The patient presents with symptoms of an acute viral illness $13$ days after a high-risk sexual exposure. This timeframe is highly suspicious for acute HIV infection, as the incubation period is typically $2$ to $4$ weeks. The symptoms themselves are characteristic of acute retroviral syndrome.\n\n2.  **Analysis of the Diagnostic Algorithm**:\n    -   **Initial Test**: A $4^{\\text{th}}$-generation HIV-$1$/HIV-$2$ antigen/antibody combination immunoassay is reactive. These assays detect two markers: the HIV p24 antigen and antibodies (IgM and IgG) to HIV-$1$ and HIV-$2$. The p24 antigen is a viral core protein that appears in the blood approximately $10$ to $14$ days after infection, peaking at around $3$ to $4$ weeks before declining as antibodies develop. Antibodies typically become detectable $3$ to $12$ weeks after infection. A reactive result on this test means that at least one of these markers (p24 antigen or antibodies) is present. Given the patient's history, the reactive test is very likely due to the presence of p24 antigen.\n\n    -   **Supplemental Test**: An HIV-$1$/HIV-$2$ antibody differentiation immunoassay is negative. This test is designed to confirm a reactive screening test and specifically detects only antibodies, differentiating between HIV-$1$ and HIV-$2$. A negative result indicates that there are no detectable levels of antibodies to either virus type.\n\n    -   **Interpretation of Discordance**: The combination of a reactive $4^{\\text{th}}$-generation test and a negative antibody-only differentiation test is a classic \"discordant\" result. The logical conclusion is that the initial test was reactive due to the presence of p24 antigen, and the patient is in the \"window period\" of acute infection where viral antigens are present, but a detectable antibody response has not yet been mounted.\n\n    -   **Tie-Breaker Test**: An HIV-$1$ RNA NAT is positive at $2.1 \\times 10^{5}$ copies/mL. The NAT directly detects the genetic material of the virus (RNA) and is the most sensitive test for detecting very early infection. A positive HIV-$1$ RNA NAT is definitive proof of active HIV-$1$ infection. The high viral load is characteristic of the unchecked viral replication that occurs during the acute phase of infection before the host immune system has mounted an effective response.\n\n3.  **Conclusion**: The patient has acute HIV-$1$ infection. The entire clinical and laboratory picture is internally consistent and points unequivocally to this diagnosis. The diagnostic algorithm performed exactly as intended, identifying an infection before seroconversion.\n\n4.  **Appropriate Clinical Action**: The diagnosis of acute HIV infection is a medical priority. Current clinical guidelines uniformly advocate for the immediate initiation of antiretroviral therapy (ART). Early treatment during this phase is associated with several benefits: it can lessen the severity of acute symptoms, reduce the extent of viral seeding in lymphoid tissues, lower the long-term viral load set point, and, most critically from a public health perspective, dramatically reduce the very high risk of transmission associated with the high viremia of acute infection. Therefore, immediate ART initiation, coupled with comprehensive counseling about the diagnosis and transmission prevention, is the standard of care. Repeating serologic testing in the subsequent weeks is clinically appropriate to document the natural course of infection, i.e., the development of antibodies (seroconversion).\n\n### Evaluation of Options\n\n**A. The reactive screening immunoassay is a false positive due to cross-reactive antibodies; the negative differentiation immunoassay rules out HIV, so defer therapy and repeat all tests in $6$ months.**\nThis is **Incorrect**. The assertion of a false positive is directly contradicted by the positive HIV-$1$ RNA NAT, which provides definitive evidence of viremia. The negative antibody differentiation assay does not rule out HIV; it is an expected finding in a very recent infection prior to seroconversion. Deferring therapy would be a serious clinical error.\n\n**B. Chronic Human Immunodeficiency Virus type $2$ (HIV-$2$) infection explains the discordance; initiate HIV-$2$-directed antiretroviral therapy (ART) and disregard the HIV-$1$ RNA NAT as nonspecific.**\nThis is **Incorrect**. The antibody differentiation assay was negative for both HIV-$1$ and HIV-$2$, arguing against chronic infection of either type. Furthermore, the HIV-$1$ RNA NAT is highly specific for HIV-$1$ and should never be disregarded as nonspecific. The positive HIV-$1$ NAT confirms HIV-$1$ infection, not HIV-$2$.\n\n**C. Acute Human Immunodeficiency Virus type $1$ (HIV-$1$) infection is present; diagnose acute HIV-$1$, initiate antiretroviral therapy (ART) immediately, provide transmission counseling, and repeat serologic testing in $1$ to $2$ weeks to document seroconversion.**\nThis is **Correct**. This option accurately interprets the laboratory data as diagnostic for acute HIV-$1$ infection. The proposed actions—immediate initiation of ART, counseling, and follow-up testing to document seroconversion—are precisely the current standard of care and are fully supported by the clinical and laboratory evidence.\n\n**D. The discordance indicates an indeterminate result without sufficient evidence for HIV; await antibody confirmation before any antiretroviral therapy (ART) or counseling.**\nThis is **Incorrect**. The result is not \"indeterminate\"; it is diagnostic of acute HIV-$1$ infection per the CDC algorithm. The positive HIV-$1$ RNA NAT is sufficient and definitive evidence of HIV infection. Awaiting antibody confirmation would dangerously delay necessary treatment and counseling.\n\n**E. A transient viremia from a non-HIV viral illness caused the positive NAT; provide supportive care only and avoid labeling the patient with HIV until antibodies appear.**\nThis is **Incorrect**. The HIV-$1$ RNA NAT is exceptionally specific and does not detect other viruses. The idea of a \"transient viremia from a non-HIV viral illness\" causing a positive HIV-$1$ NAT is biologically unsupported. The combination of a reactive $4^{\\text{th}}$-generation immunoassay (detecting p24 antigen) and a positive HIV-$1$ RNA NAT (detecting viral RNA) confirms the diagnosis of HIV-$1$ infection. Withholding a diagnosis and treatment would be contrary to all established medical guidelines.", "answer": "$$\\boxed{C}$$", "id": "4848448"}, {"introduction": "Once antiretroviral therapy (ART) is initiated, quantitatively assessing its effectiveness is a core task in HIV management. The magnitude of viral load reduction is a key early predictor of long-term success. This practice problem [@problem_id:4848442] provides a hands-on opportunity to apply logarithmic calculations to real-world viral load data, translating raw numbers into a standardized measure of treatment response and judging its clinical adequacy.", "problem": "A 34-year-old person with newly diagnosed Human Immunodeficiency Virus (HIV) infection initiates antiretroviral therapy (ART) with a guideline-recommended integrase strand transfer inhibitor–based regimen at time $t=0$. Plasma HIV-1 ribonucleic acid (RNA) viral load is quantified using a Food and Drug Administration (FDA)-cleared assay at two time points: baseline $t=0$ and week $t=8$. The measured viral loads are $4.8 \\times 10^{5}$ copies/mL at $t=0$ and $1.8 \\times 10^{3}$ copies/mL at $t=8$. Using first principles for base-$10$ logarithms and the clinical convention that early virologic response is assessed by the base-$10$ logarithmic change in viral load from baseline, compute the base-$10$ logarithmic decline in viral load from baseline to week $8$. Then, based on well-established clinical benchmarks that an effective regimen typically produces at least a $2$ $\\log_{10}$ decline in viral load by weeks $8$ to $12$, interpret whether the response is adequate. \n\nReport only the base-$10$ logarithmic decline as a dimensionless number. Round your answer to four significant figures. Do not include units in your final numerical answer. The clinical interpretation should appear only in your reasoning, not in your final answer.", "solution": "The problem is validated as scientifically grounded, well-posed, and objective. It presents a standard clinical scenario in internal medicine, specifically the management of HIV infection, and requires a calculation based on fundamental mathematical principles and established clinical practice. All necessary data are provided, and the problem is internally consistent.\n\nThe primary task is to compute the base-$10$ logarithmic decline in plasma HIV-1 RNA viral load from a baseline measurement to a measurement at week $8$. Let the viral load at baseline ($t=0$) be denoted by $V_0$ and the viral load at time $t$ be denoted by $V_t$.\n\nThe given values are:\nBaseline viral load at $t=0$: $V_0 = 4.8 \\times 10^{5}$ copies/mL.\nViral load at $t=8$ weeks: $V_8 = 1.8 \\times 10^{3}$ copies/mL.\n\nThe base-$10$ logarithmic decline, which we shall denote as $\\Delta L$, is defined as the difference between the logarithm of the baseline viral load and the logarithm of the viral load at the subsequent time point. Mathematically, this is expressed as:\n$$\n\\Delta L = \\log_{10}(V_0) - \\log_{10}(V_8)\n$$\nUsing the fundamental property of logarithms, which states that $\\log_b(x) - \\log_b(y) = \\log_b\\left(\\frac{x}{y}\\right)$, we can simplify the expression for the logarithmic decline:\n$$\n\\Delta L = \\log_{10}\\left(\\frac{V_0}{V_8}\\right)\n$$\nNow, we substitute the provided numerical values for $V_0$ and $V_8$ into this equation.\n$$\n\\Delta L = \\log_{10}\\left(\\frac{4.8 \\times 10^{5}}{1.8 \\times 10^{3}}\\right)\n$$\nTo compute this, we first evaluate the ratio inside the logarithm:\n$$\n\\frac{V_0}{V_8} = \\frac{4.8 \\times 10^{5}}{1.8 \\times 10^{3}} = \\frac{4.8}{1.8} \\times 10^{5-3} = \\frac{48}{18} \\times 10^{2}\n$$\nThe fraction $\\frac{48}{18}$ can be simplified by dividing both the numerator and the denominator by their greatest common divisor, which is $6$:\n$$\n\\frac{48}{18} = \\frac{8 \\times 6}{3 \\times 6} = \\frac{8}{3}\n$$\nThus, the ratio is:\n$$\n\\frac{V_0}{V_8} = \\frac{8}{3} \\times 10^{2} = \\frac{800}{3}\n$$\nSubstituting this back into the expression for $\\Delta L$:\n$$\n\\Delta L = \\log_{10}\\left(\\frac{800}{3}\\right)\n$$\nThe numerical value of this expression is calculated as:\n$$\n\\Delta L \\approx \\log_{10}(266.666...) \\approx 2.4259687...\n$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures of the result $2.4259687...$ are $2$, $4$, $2$, and $5$. The fifth significant figure is $9$, which is greater than or equal to $5$, so we must round up the fourth significant figure.\n$$\n\\Delta L \\approx 2.426\n$$\nThe problem also asks for a clinical interpretation based on the given benchmark. The benchmark for an effective antiretroviral regimen is a viral load decline of at least $2 \\log_{10}$ by weeks $8$ to $12$. The calculated decline is approximately $2.426 \\log_{10}$. Since $2.426  2$, the observed virologic response is considered adequate and indicates that the initiated antiretroviral therapy is effective. This interpretation, however, is part of the reasoning and is not included in the final numerical answer as per the instructions. The final answer is the dimensionless numerical value of the logarithmic decline.", "answer": "$$\\boxed{2.426}$$", "id": "4848442"}, {"introduction": "As HIV becomes a manageable chronic condition, clinicians must increasingly navigate complex drug-drug interactions when treating comorbidities like hyperlipidemia. This problem [@problem_id:4848409] moves beyond simple contraindications to a quantitative application of pharmacokinetic principles, allowing you to predict how a potent ART component can alter the systemic exposure of commonly used statins. Mastering this skill is essential for safely prescribing medications to patients on modern antiretroviral regimens.", "problem": "A patient with Human Immunodeficiency Virus (HIV) infection is prescribed a ritonavir-boosted protease inhibitor (PI) regimen for Antiretroviral Therapy (ART). The patient has hyperlipidemia requiring statin therapy. Because of known severe cytochrome P450 3A4 interactions, simvastatin is avoided. You are to assess the expected changes in statin systemic exposure under this PI regimen using pharmacokinetic principles and compute the Area Under the Curve (AUC) fold-change for four candidate statins in the following fixed order: atorvastatin, rosuvastatin, pravastatin, and pitavastatin.\n\nUse the following fundamental base: for a single oral dose, the systemic exposure quantified by AUC is determined by oral bioavailability $F$ and total clearance $CL$ via the relationship\n$$\n\\mathrm{AUC} = \\frac{F \\cdot D}{CL},\n$$\nwhere $D$ is the administered dose. Assume linear pharmacokinetics and that $D$ is held constant. Under ritonavir boosting, the following scientifically plausible fractional changes in oral bioavailability and clearance are observed for each statin due to intestinal and hepatic enzyme and transporter inhibition:\n\n- Atorvastatin: $F$ increases by $60\\%$ (i.e., $F^{*} = 1.60 \\, F$) and $CL$ decreases by $50\\%$ (i.e., $CL^{*} = 0.50 \\, CL$).\n- Rosuvastatin: $F$ increases by $25\\%$ (i.e., $F^{*} = 1.25 \\, F$) and $CL$ decreases by $20\\%$ (i.e., $CL^{*} = 0.80 \\, CL$).\n- Pravastatin: $F$ increases by $10\\%$ (i.e., $F^{*} = 1.10 \\, F$) and $CL$ decreases by $5\\%$ (i.e., $CL^{*} = 0.95 \\, CL$).\n- Pitavastatin: $F$ increases by $5\\%$ (i.e., $F^{*} = 1.05 \\, F$) and $CL$ is unchanged (i.e., $CL^{*} = 1.00 \\, CL$).\n\nCompute the AUC fold-change ratio $R$ for each statin, defined as\n$$\nR = \\frac{\\mathrm{AUC}^{*}}{\\mathrm{AUC}},\n$$\nand report your final answer as a single row matrix in the stated statin order. Round your answer to four significant figures. Express the final values as dimensionless numbers without any units.", "solution": "The problem asks for the computation of the Area Under the Curve (AUC) fold-change for four different statins when co-administered with a ritonavir-boosted protease inhibitor regimen. The analysis relies on fundamental pharmacokinetic principles.\n\nThe starting point is the given relationship for the AUC for a single oral dose, assuming linear pharmacokinetics:\n$$\n\\mathrm{AUC} = \\frac{F \\cdot D}{CL}\n$$\nwhere $F$ is the oral bioavailability, $D$ is the administered dose, and $CL$ is the total systemic clearance of the drug.\n\nWe are asked to compute the fold-change ratio, $R$, defined as the ratio of the AUC in the presence of the inhibitor (denoted by a superscript asterisk, $\\mathrm{AUC}^{*}$) to the baseline AUC without the inhibitor ($\\mathrm{AUC}$).\n$$\nR = \\frac{\\mathrm{AUC}^{*}}{\\mathrm{AUC}}\n$$\nLet $F^{*}$ and $CL^{*}$ be the bioavailability and clearance in the presence of ritonavir, respectively. The dose, $D$, is stated to be held constant. Substituting the expression for AUC into the ratio $R$, we have:\n$$\nR = \\frac{\\left(\\frac{F^{*} \\cdot D}{CL^{*}}\\right)}{\\left(\\frac{F \\cdot D}{CL}\\right)}\n$$\nThe dose $D$ cancels from the numerator and denominator. We can rearrange the expression to group the bioavailability and clearance terms:\n$$\nR = \\frac{F^{*}}{CL^{*}} \\cdot \\frac{CL}{F} = \\left(\\frac{F^{*}}{F}\\right) \\cdot \\left(\\frac{CL}{CL^{*}}\\right) = \\left(\\frac{F^{*}}{F}\\right) \\cdot \\left(\\frac{CL^{*}}{CL}\\right)^{-1}\n$$\nThis simplified equation shows that the AUC fold-change is the product of the bioavailability fold-change and the inverse of the clearance fold-change. We will now apply this formula to each of the four statins using the provided data.\n\n1.  **Atorvastatin**:\n    The given changes are an increase in $F$ by $60\\%$ and a decrease in $CL$ by $50\\%$. This translates to:\n    $$\n    F^{*} = 1.60 \\cdot F \\implies \\frac{F^{*}}{F} = 1.60\n    $$\n    $$\n    CL^{*} = 0.50 \\cdot CL \\implies \\frac{CL^{*}}{CL} = 0.50\n    $$\n    The AUC fold-change, $R_{\\mathrm{atorva}}$, is:\n    $$\n    R_{\\mathrm{atorva}} = \\left(\\frac{F^{*}}{F}\\right) \\cdot \\left(\\frac{CL}{CL^{*}}\\right) = 1.60 \\cdot \\left(\\frac{1}{0.50}\\right) = 1.60 \\cdot 2 = 3.2\n    $$\n\n2.  **Rosuvastatin**:\n    The given changes are an increase in $F$ by $25\\%$ and a decrease in $CL$ by $20\\%$. This translates to:\n    $$\n    F^{*} = 1.25 \\cdot F \\implies \\frac{F^{*}}{F} = 1.25\n    $$\n    $$\n    CL^{*} = 0.80 \\cdot CL \\implies \\frac{CL^{*}}{CL} = 0.80\n    $$\n    The AUC fold-change, $R_{\\mathrm{rosuva}}$, is:\n    $$\n    R_{\\mathrm{rosuva}} = \\left(\\frac{F^{*}}{F}\\right) \\cdot \\left(\\frac{CL}{CL^{*}}\\right) = 1.25 \\cdot \\left(\\frac{1}{0.80}\\right) = 1.25 \\cdot 1.25 = 1.5625\n    $$\n\n3.  **Pravastatin**:\n    The given changes are an increase in $F$ by $10\\%$ and a decrease in $CL$ by $5\\%$. This translates to:\n    $$\n    F^{*} = 1.10 \\cdot F \\implies \\frac{F^{*}}{F} = 1.10\n    $$\n    $$\n    CL^{*} = 0.95 \\cdot CL \\implies \\frac{CL^{*}}{CL} = 0.95\n    $$\n    The AUC fold-change, $R_{\\mathrm{prava}}$, is:\n    $$\n    R_{\\mathrm{prava}} = \\left(\\frac{F^{*}}{F}\\right) \\cdot \\left(\\frac{CL}{CL^{*}}\\right) = 1.10 \\cdot \\left(\\frac{1}{0.95}\\right) = \\frac{1.10}{0.95} \\approx 1.1578947...\n    $$\n\n4.  **Pitavastatin**:\n    The given changes are an increase in $F$ by $5\\%$ and no change in $CL$. This translates to:\n    $$\n    F^{*} = 1.05 \\cdot F \\implies \\frac{F^{*}}{F} = 1.05\n    $$\n    $$\n    CL^{*} = 1.00 \\cdot CL \\implies \\frac{CL^{*}}{CL} = 1.00\n    $$\n    The AUC fold-change, $R_{\\mathrm{pita}}$, is:\n    $$\n    R_{\\mathrm{pita}} = \\left(\\frac{F^{*}}{F}\\right) \\cdot \\left(\\frac{CL}{CL^{*}}\\right) = 1.05 \\cdot \\left(\\frac{1}{1.00}\\right) = 1.05\n    $$\n\nThe problem requires the final answers to be rounded to four significant figures.\n- For Atorvastatin: $3.2$ becomes $3.200$.\n- For Rosuvastatin: $1.5625$ rounds to $1.563$.\n- For Pravastatin: $1.1578947...$ rounds to $1.158$.\n- For Pitavastatin: $1.05$ becomes $1.050$.\n\nThe final answer is to be presented as a single row matrix containing these four values in the specified order: atorvastatin, rosuvastatin, pravastatin, and pitavastatin.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n3.200  1.563  1.158  1.050\n\\end{pmatrix}\n}\n$$", "id": "4848409"}]}